- Home
- MGNX vs PLL Comparison
MGNX vs PLL Comparison
Compare MGNX & PLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- PLL
- Stock Information
- Founded
- MGNX 2000
- PLL 2016
- Country
- MGNX United States
- PLL United States
- Employees
- MGNX N/A
- PLL N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- PLL Other Metals and Minerals
- Sector
- MGNX Health Care
- PLL Basic Materials
- Exchange
- MGNX Nasdaq
- PLL Nasdaq
- Market Cap
- MGNX 257.3M
- PLL 238.0M
- IPO Year
- MGNX 2013
- PLL 2017
- Fundamental
- Price
- MGNX $3.24
- PLL $13.28
- Analyst Decision
- MGNX Buy
- PLL Buy
- Analyst Count
- MGNX 11
- PLL 9
- Target Price
- MGNX $8.57
- PLL $21.33
- AVG Volume (30 Days)
- MGNX 770.4K
- PLL 898.6K
- Earning Date
- MGNX 11-05-2024
- PLL 11-12-2024
- Dividend Yield
- MGNX N/A
- PLL N/A
- EPS Growth
- MGNX N/A
- PLL N/A
- EPS
- MGNX N/A
- PLL N/A
- Revenue
- MGNX $141,329,000.00
- PLL $46,981,000.00
- Revenue This Year
- MGNX $119.63
- PLL $155.85
- Revenue Next Year
- MGNX N/A
- PLL $13.29
- P/E Ratio
- MGNX N/A
- PLL N/A
- Revenue Growth
- MGNX 16.68
- PLL N/A
- 52 Week Low
- MGNX $2.95
- PLL $6.57
- 52 Week High
- MGNX $21.88
- PLL $31.82
- Technical
- Relative Strength Index (RSI)
- MGNX 37.79
- PLL 55.62
- Support Level
- MGNX $3.61
- PLL $9.77
- Resistance Level
- MGNX $5.10
- PLL $13.25
- Average True Range (ATR)
- MGNX 0.35
- PLL 1.31
- MACD
- MGNX -0.10
- PLL -0.10
- Stochastic Oscillator
- MGNX 4.62
- PLL 72.69
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About PLL Piedmont Lithium Inc.
Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.